OakChart

City Therapeutics Inc

CTYHealthcare·Biotechnology·USA·Small·NASD·Nov 12 • 11:04 AM ET

18.56+1.55 (9.11%)
2026-11-12 17:05 CET
Market cap
- USD m
Revenue, TTM
- USD m
Net income, TTM
- USD m
Free cash flow, TTM
- USD m
EPS diluted, TTM
-
P/E
-
Compare

Price

CTY against its 20-day averages
20
Patternshover a marker to name it
EPS mean, own scale
EPS -1.96Price-1.9616.0018.0020.0022.0024.00703K1.4MVolumeOct 26Nov 26CTYclose 18.5620-day 19.9218.5652w high52w low

22.3% under the 52-week high of 23.88 on 16 Oct 2026. 52-week low 15.81 on 5 Nov 2026. Last 15 sessions, 43.3% high to low. This session is unfinished.

Volume 0.92× normal · the line is the 50-bar volume average

Profile

CTY
52-week range, 34% of the way up
15.8123.88

City Therapeutics, Inc. operates as a clinical-stage biotechnology company. It engages in the development of RNAi therapeutics. The company was founded by John Maraganore, Sebastian Trousil, Ari Nowacek, Mark Keating, Kotaro Nakanishi, Yukihide Tomari, and Phillip Zamore on July 17, 2023 and is headquartered in Cambridge, MA.

IPOOct 16, 2026
ATR, 14d2.03
Rel volume0.92
Short float2.65%
Insider own39.99%
Inst own14.70%

Snapshot

6 groups

Valuation

Index-
Market Cap959.95M
Enterprise Value-
Income-
Sales-
Book/sh-
Cash/sh-
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees-
IPOOct 16, 2026

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B-
P/C-
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio-
Current Ratio-
Debt/Eq-
LT Debt/Eq-
Option/ShortNo / Yes

Earnings

EPS (ttm)-
EPS next Y-
EPS next Q-1.96
EPS this Y-
EPS next Y-
EPS next 5Y-
EPS past 3/5Y- -
Sales past 3/5Y- -
EPS Y/Y TTM-
Sales Y/Y TTM-
EPS Q/Q-
Sales Q/Q-
EarningsSep 02
EPS/Sales Surpr.- -

Ownership

Insider Own39.99%
Insider Trans1.67%
Inst Own14.70%
Inst Trans17.17%
ROA-
ROE-
ROIC-
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-6.82%
SMA50-6.82%
SMA200-6.82%
Trades-

Technical

Shs Outstand50.33M
Shs Float31.04M
Short Float2.65%
Short Ratio2.39
Short Interest0.82M
52W High23.88 -22.28%
52W Low15.81 17.39%
Volatility12.53% -
ATR (14)2.03
RSI (14)40.45
Beta-
Rel Volume0.92
Avg Volume344.39K
Volume88,501

Performance

Perf Week8.73%
Perf Month-
Perf Quarter-
Perf Half Y-
Perf YTD-19.30%
Perf Year-
Perf 3Y-
Perf 5Y-
Perf 10Y-
Recom1.00
Target Price37.33
Prev Close17.01
Price18.56
Change %9.11%

Analyst ratings

latest 3 of 3
DateActionAnalystRating changeTargetImplied
Nov 10, 2026InitiatedSStifelBuy$34+83.2%
Nov 10, 2026InitiatedOOppenheimerOutperform$46+147.8%
Nov 10, 2026InitiatedJJefferiesBuy$32+72.4%

Peers

Mkt cap
TickerCompanyMkt cap
ARWRArrowhead Pharmaceuticals Inc6.79B
SLNSilence Therapeutics Plc ADR1.23B
WVEWave Life Sciences Inc666.34M
ALNYAlnylam Pharmaceuticals Inc21.10B
ABUSArbutus Biopharma Corp594.67M
IONSIonis Pharmaceuticals Inc4.57B
DYNDyne Therapeutics Inc3.30B
BLTEBelite Bio Inc ADR6.77B
KRROKorro Bio Inc193.05M
PRQRProQR Therapeutics N.V191.92M

Insider trading

2 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
ARCH Venture Partners XII, LLC10% OwnerOct 19 '26Buy18.00170,0003,060,00013,692,507Oct 19 05:38 PM
NELSEN ROBERTDirectorOct 19 '26Buy18.00170,0003,060,00013,692,507Oct 19 05:37 PM

Held by

AUM
TickerCompanyAUM
HRTSTema Heart & Health ETFAUM: 58.27M
HLTHTema Healthcare AI ETFAUM: 11.46M
TDNAT. Rowe Price Biotech ETFAUM: 11.51M

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-09-02-0.550-----
2026Q3---1.963--5.004
2026Q4---0.595--15.334
2027Q1---0.680--0.001
2027Q2---0.790--0.001
2027Q3---0.620--15.001

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
No annual earnings.

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-11-093005.000.0012.00
2026Q3R2026-11-09200-3.14-3.75-2.52
2026Q3E2026-11-09400-1.96-3.75-0.32

Estimate history

EPS, annual
Period
EPS, quarterly
Period
Sales, annual
Period
Sales, quarterly
Period
Shares, annual
Period
Shares, quarterly
Period

Income statement, annual

No statement data.

Income statement, quarterly

No statement data.

Balance sheet, annual

No statement data.

Cash flow, annual

No statement data.

Balance sheet, quarterly

No statement data.

Cash flow, quarterly

No statement data.

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-302.65%0.8M31.0M366.39K

Option chain

expiry 2026-11-12
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-108-KCurrent report2026-11-10SEC
2026-11-06SCHEDULE 13GSEC
2026-10-26SCHEDULE 13DSEC
2026-10-26SCHEDULE 13GSEC
2026-10-22SCHEDULE 13GSEC
2026-10-194Statement of changes in beneficial ownership of securities2026-10-19SEC
2026-10-194Statement of changes in beneficial ownership of securities2026-10-15SEC
2026-10-194Statement of changes in beneficial ownership of securities2026-10-15SEC
2026-10-194Statement of changes in beneficial ownership of securities2026-10-15SEC
2026-10-194Statement of changes in beneficial ownership of securities2026-10-19SEC
2026-10-194Statement of changes in beneficial ownership of securities2026-10-15SEC
2026-10-194Statement of changes in beneficial ownership of securities2026-10-15SEC
2026-10-198-KCurrent report2026-10-15SEC
2026-10-16S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-10-16424B4SEC
2026-10-15EFFECTEffectiveness filing by commission orderSEC
2026-10-15CERTSEC
2026-10-15S-1MEFA new registration statement filed under Rule 462(b) to add securities to a prior related effective registration statement filed on Form S-1SEC
2026-10-153Initial statement of beneficial ownership of securities2026-10-15SEC
2026-10-153Initial statement of beneficial ownership of securities2026-10-15SEC
2026-10-153Initial statement of beneficial ownership of securities2026-10-15SEC
2026-10-153Initial statement of beneficial ownership of securities2026-10-15SEC
2026-10-153Initial statement of beneficial ownership of securities2026-10-15SEC
2026-10-153Initial statement of beneficial ownership of securities2026-10-15SEC
2026-10-153Initial statement of beneficial ownership of securities2026-10-15SEC
2026-10-153Initial statement of beneficial ownership of securities2026-10-15SEC
2026-10-153Initial statement of beneficial ownership of securities2026-10-15SEC
2026-10-153Initial statement of beneficial ownership of securities2026-10-15SEC
2026-10-153Initial statement of beneficial ownership of securities2026-10-15SEC
2026-10-138-A12BSEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-106.12M200
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
-

Funds

Fund% owned
-

OakChart. CTY. Cached 15 minutes.

Some panels did not load: news.